Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $1.76 in the prior trading day, Evogene Ltd (NASDAQ: EVGN) closed at $1.66, down -5.68%. In other words, the price has decreased by -$5.68 from its previous closing price. On the day, 55753.0 shares were traded. EVGN stock price reached its highest trading level at $1.73 during the session, while it also had its lowest trading level at $1.6.
Ratios:
Our goal is to gain a better understanding of EVGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.03 and its Current Ratio is at 1.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, ROTH Capital on October 08, 2021, initiated with a Buy rating and assigned the stock a target price of $7.
On July 29, 2021, Aegis Capital started tracking the stock assigning a Buy rating and target price of $10.
On December 01, 2020, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $9.Cantor Fitzgerald initiated its Overweight rating on December 01, 2020, with a $9 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EVGN now has a Market Capitalization of 11159947 and an Enterprise Value of 5184654. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.19. Its current Enterprise Value per Revenue stands at 0.549 whereas that against EBITDA is -0.264.
Stock Price History:
The Beta on a monthly basis for EVGN is 1.30, which has changed by -0.82526314 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, EVGN has reached a high of $10.40, while it has fallen to a 52-week low of $1.20. The 50-Day Moving Average of the stock is -2.83%, while the 200-Day Moving Average is calculated to be -62.32%.
Shares Statistics:
The stock has traded on average 298.93K shares per day over the past 3-months and 84600 shares per day over the last 10 days, according to various share statistics. A total of 6.79M shares are outstanding, with a floating share count of 5.28M. Insiders hold about 1.56% of the company’s shares, while institutions hold 11.27% stake in the company. Shares short for EVGN as of 1730332800 were 22354 with a Short Ratio of 0.13, compared to 1727654400 on 14621. Therefore, it implies a Short% of Shares Outstanding of 22354 and a Short% of Float of 0.42.
Earnings Estimates
The current assessment of Evogene Ltd (EVGN) involves the perspectives of 2.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.73, with high estimates of -$0.73 and low estimates of -$0.73.
Analysts are recommending an EPS of between -$3.88 and -$4.35 for the fiscal current year, implying an average EPS of -$4.11. EPS for the following year is -$3.11, with 2.0 analysts recommending between -$3.02 and -$3.2.
Revenue Estimates
2 analysts predict $3.62M in revenue for the current quarter. It ranges from a high estimate of $3.75M to a low estimate of $3.5M. As of the current estimate, Evogene Ltd’s year-ago sales were $578kFor the next quarter, 2 analysts are estimating revenue of $4M. There is a high estimate of $4M for the next quarter, whereas the lowest estimate is $4M.
A total of 2 analysts have provided revenue estimates for EVGN’s current fiscal year. The highest revenue estimate was $10.65M, while the lowest revenue estimate was $10.4M, resulting in an average revenue estimate of $10.53M. In the same quarter a year ago, actual revenue was $5.64MBased on 2 analysts’ estimates, the company’s revenue will be $14.6M in the next fiscal year. The high estimate is $16.2M and the low estimate is $13M.
